Late-onset Graves’ disease after hemithyroidectomy: a case report Authors: Sayaka Mabuchi, Naoko Adachi, Atsushi Nagasawa, Satoshi Nabika, Kazumi Notsu Published: 2026 ABSTRACT BackgroundAmong hyperthyroidism cases, Graves’ disease is the most common, with incidence peaking between 30 and 60 years of age. Hemithyroidectomy is sometimes performed for conditions such as thyroid tumors, and Graves’ disease may develop from the residual thyroid tissue postoperatively. The occurrence of Graves’ disease in the residual thyroid gland after resection of neoplastic lesions is very rare. Here, we present two cases of patients in their 70 s who developed Graves’ disease years after hemithyroidectomy, along with a literature review.Case presentationCase 1 involved a 71-year-old Japanese female who underwent left hemithyroidectomy for papillary cancer. Three years postoperatively, she was diagnosed with Graves’ disease. Case 2 concerned a 75-year-old Japanese female who underwent left hemithyroidectomy, with pathology confirming a follicular adenoma. Eight years after the operation, she was diagnosed with Graves’ disease.ConclusionsIt is rare for a patient to develop Graves’ disease many years after hemithyroidectomy. A possible leakage of thyroid antigens may be involved; however, attributing cases that develop several years later to the effects of surgery remains uncertain. It is possible that a certain period passed with subclinical Graves’ disease, even if thyroid-stimulating hormone receptor antibody (TRAb) and thyroid-stimulating antibody were produced under the influence of surgery. If the surgical effect was limited, patients may have developed Graves’ disease from Hashimoto’s disease. If TRAb had been measured during postoperative follow-up, it could have led to an earlier diagnosis. Background Graves’ disease is an organ-specific autoimmune disease in which thyroid-stimulating hormone receptor antibody (TRAb) stimulates the thyroid-stimulating hormone receptor on thyroid follicular cells, resulting in increased thyroid follicular cell proliferation and thyroid hormone synthesis [1]. Genetic predisposition accounts for 79% of cases, while environmental factors (e.g., smoking, iodine excess, selenium, and vitamin D deficiency) contribute to the remaining 21% [2]. Among hyperthyroid disorders, Graves’ disease is the most common, with an annual incidence of 20–50 cases per 100,000 persons [2, 3]; in Japan in 2001, its prevalence was estimated at 0.073–0.11% [4]. The incidence peaks between 30 and 60 years of age, which is relatively young [2, 3]. Because symptoms in older patients are less pronounced than those in younger patients, diagnosing Graves’ disease in older patients—termed apathetic or masked hyperthyroidism [5]—is sometimes difficult. Treatment options for Graves’ disease include antithyroid medications, radiation therapy, and surgery, with total thyroidectomy being the most frequently performed surgical procedure [3, 6]. Hemithyroidectomy is sometimes performed for reasons such as the presence of tumors, and Graves’ disease may develop from the residual thyroid postoperatively [7–15]. New-onset Graves’ disease after hemithyroidectomy is very uncommon (0.24%), with only a few cases reported [10]. It has been postulated that, in the immediate postoperative period, thyroid follicular cells may be damaged by surgery, releasing autoantigens and triggering an immune response [7]. However, there have been a few reports of patients who developed Graves’ disease several years after hemithyroidectomy, and the underlying mechanism remains unknown. Herein, we present two cases of patients in their early 70 s who developed Graves’ disease years after hemithyroidectomy and discuss previously published relevant literature. Case presentation Case 1 This case involved a 71-year-old Japanese female who underwent left hemithyroidectomy for papillary cancer at the age of 68 years. She had no family history of thyroid diseases. She began taking levothyroxine (L-T4) 25 μg due to postoperative hypothyroidism. She had been monitored for thyroid function; however, her serum results revealed thyrotoxicosis 3 years after the operation (Table 1). L-T4 was discontinued, but thyrotoxicosis persisted. On physical examination, a surgical scar was noted on her neck, and she exhibited a finger tremor without exophthalmos. She was ultimately diagnosed with Graves’ disease based on repeated blood tests showing high free thyroxine 3 and free thyroxine 4, low thyroid-stimulating hormone, and positive TRAb (Table 1). Drug therapy with methimazole (MMI) 15 mg/day was initiated, resulting in normalization of thyroid function. Her thyroid level was well controlled with MMI 5 mg/day; therefore, treatment options such as radioiodine and total thyroidectomy were not considered.Table 1Laboratory test of Case 1Laboratory parameterBefore operationThree years after the operationTSH (μU/mL)4.390.005FT3 (pg/mL)n.t12.60FT4 (ng/dL)1.103.34TRAb (IU/L)n.t40.1TgAb (IU/mL)262493TPOAb (IU/mL)205n.tTg (ng/mL)19.713.80n.t. not tested, FT3 free triiodothyronine, FT4 free thyroxine, Tg thyroglobulin, TgAb thyroglobulin Antibody, TPOAb thyroid peroxidase antibody, TRAb thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormone Table 1Laboratory test of Case 1Laboratory parameterBefore operationThree years after the operationTSH (μU/mL)4.390.005FT3 (pg/mL)n.t12.60FT4 (ng/dL)1.103.34TRAb (IU/L)n.t40.1TgAb (IU/mL)262493TPOAb (IU/mL)205n.tTg (ng/mL)19.713.80n.t. not tested, FT3 free triiodothyronine, FT4 free thyroxine, Tg thyroglobulin, TgAb thyroglobulin Antibody, TPOAb thyroid peroxidase antibody, TRAb thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormone Laboratory test of Case 1 n.t. not tested, FT3 free triiodothyronine, FT4 free thyroxine, Tg thyroglobulin, TgAb thyroglobulin Antibody, TPOAb thyroid peroxidase antibody, TRAb thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormone Case 2 This case involved a 75-year-old Japanese female who underwent left hemithyroidectomy at the age of 67 years, with pathology revealing a follicular adenoma. She had no family history of thyroid diseases. Postoperatively, she was started on L-T4 100 μg for hypothyroidism. She underwent regular thyroid function checks; however, serum results indicated thyrotoxicosis 8 years after the operation (Table 2). L-T4 was discontinued, but thyrotoxicosis persisted. The patient experienced palpitations and exertional dyspnea. On physical examination, a surgical scar was noted on her neck, and she exhibited a finger tremor without exophthalmos. She was ultimately diagnosed with Graves’ disease based on repeat blood tests (including positive TRAb) and technetium scintigraphy (Table 2 and Fig. 1). Drug therapy with MMI 30 mg/day was initiated, leading to normalization of thyroid function. Her thyroid level was well controlled with MMI 5 mg/day since 4 months after onset of Graves’ disease; therefore, treatment options such as radioiodine and total thyroidectomy were not considered.Table 2Laboratory test of Case 2Laboratory parameterEight years after the operationTSH (μU/mL) < 0.1FT3 (pg/mL) > 26.2FT4 (ng/dL) > 9.3TRAb (IU/L)52.6TgAb (IU/mL) < 0.4TPOAb (IU/mL) < 0.3Tg (ng/mL)263FT3 free triiodothyronine, FT4 free thyroxine, Tg thyroglobulin, TgAb thyroglobulin antibody, TPOAb thyroid peroxidase antibody, TRAb thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormoneFig. 199 Technetium scintigraphy of Case 2 Table 2Laboratory test of Case 2Laboratory parameterEight years after the operationTSH (μU/mL) < 0.1FT3 (pg/mL) > 26.2FT4 (ng/dL) > 9.3TRAb (IU/L)52.6TgAb (IU/mL) < 0.4TPOAb (IU/mL) < 0.3Tg (ng/mL)263FT3 free triiodothyronine, FT4 free thyroxine, Tg thyroglobulin, TgAb thyroglobulin antibody, TPOAb thyroid peroxidase antibody, TRAb thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormone Laboratory test of Case 2 FT3 free triiodothyronine, FT4 free thyroxine, Tg thyroglobulin, TgAb thyroglobulin antibody, TPOAb thyroid peroxidase antibody, TRAb thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormone 99 Technetium scintigraphy of Case 2 Discussion These cases illustrate two points: (1) it was rare for a patient to develop Graves’ disease several years after a hemithyroidectomy, and (2) both patients were considerably older than the age at which Graves’ disease is most commonly observed. New-onset Graves’ disease after hemithyroidectomy is very rare, with only 18 cases reported, including our two cases (Table 3) [7–15]. The most common causes of hyperthyroidism after thyroidectomy are thyroid hormone replacement, followed by palpable thyroiditis (e.g., surgery and trauma), residual functional thyroid nodules, functional thyroid metastases, and other drugs (e.g., amiodarone) [16]. The frequency of Graves’ disease arising from the residual thyroid gland after resection of neoplastic lesions is estimated at 0.24%, which is extremely rare compared with the 8% incidence observed 5 years after subtotal thyroidectomy for Graves’ disease [10].Table 3Cases of new Graves’ disease developing after hemithyroidectomyCaseAgeSexLobectomyPathologyDurationHashimoto diseaseLiterature140FemaleLeftPapillary carcinoma1 month + TgAb 15–18[7]241FemaleRightPapillary carcinoma9 months + TgAb 335.8TPOAb 39.6[8]351MaleLeftPapillary carcinoma12 years + TGPA 102400MCPA102,400[9]447FemaleRightPapillary carcinoma22 years + MCPA 1600[9]532FemaleRightPapillary carcinoma7 weeks + TGPA100–400MCPA400–1600[9]649FemaleLeftPapillary carcinoma14 years + [10]758FemaleRightPapillary carcinoma8 years 6 months + [12]861FemaleRightPapillary carcinoma14 monthsunknown[13]951FemaleLeftPapillary carcinoma1 year 10 months + [14]1062FemaleLeftPapillary carcinoma3 years 8 months + [15]1171FemaleLeftPapillary carcinoma3 years + TgAb262–493TPOAb 205Case 1, present report1265FemaleRightFollicular carcinoma27 years + [10]1375FemaleLeftFollicular adenoma8 years-TgAb < 0.4TPOAb < 0.3Case 2, present report1473FemaleLeftBenign thyroid tumor4 years–[10]1551FemaleRightBenign thyroid tumor2 years + [10]1633FemaleRightAdenomatous goiter8 years–[11]1764FemaleLeftAdenomatous goiter7 days–[12]1859FemaleLeftAdenomatous nodule7 years 7 months + [15]Age refers to the age at diagnosis of Graves’ diseaseTGPA thyroglobulin particle agglutination assay, MCPA microsome particle agglutination assay Table 3Cases of new Graves’ disease developing after hemithyroidectomyCaseAgeSexLobectomyPathologyDurationHashimoto diseaseLiterature140FemaleLeftPapillary carcinoma1 month + TgAb 15–18[7]241FemaleRightPapillary carcinoma9 months + TgAb 335.8TPOAb 39.6[8]351MaleLeftPapillary carcinoma12 years + TGPA 102400MCPA102,400[9]447FemaleRightPapillary carcinoma22 years + MCPA 1600[9]532FemaleRightPapillary carcinoma7 weeks + TGPA100–400MCPA400–1600[9]649FemaleLeftPapillary carcinoma14 years + [10]758FemaleRightPapillary carcinoma8 years 6 months + [12]861FemaleRightPapillary carcinoma14 monthsunknown[13]951FemaleLeftPapillary carcinoma1 year 10 months + [14]1062FemaleLeftPapillary carcinoma3 years 8 months + [15]1171FemaleLeftPapillary carcinoma3 years + TgAb262–493TPOAb 205Case 1, present report1265FemaleRightFollicular carcinoma27 years + [10]1375FemaleLeftFollicular adenoma8 years-TgAb < 0.4TPOAb < 0.3Case 2, present report1473FemaleLeftBenign thyroid tumor4 years–[10]1551FemaleRightBenign thyroid tumor2 years + [10]1633FemaleRightAdenomatous goiter8 years–[11]1764FemaleLeftAdenomatous goiter7 days–[12]1859FemaleLeftAdenomatous nodule7 years 7 months + [15]Age refers to the age at diagnosis of Graves’ diseaseTGPA thyroglobulin particle agglutination assay, MCPA microsome particle agglutination assay Cases of new Graves’ disease developing after hemithyroidectomy + TgAb 15–18 + TgAb 335.8 TPOAb 39.6 + TGPA 102400 MCPA 102,400 + MCPA 1600 + TGPA 100–400 MCPA 400–1600 + TgAb 262–493 TPOAb 205 - TgAb < 0.4 TPOAb < 0.3 Age refers to the age at diagnosis of Graves’ disease TGPA thyroglobulin particle agglutination assay, MCPA microsome particle agglutination assay Several hypotheses have been proposed to explain the development of post-surgical Graves' disease. First, leakage of thyroid antigen due to surgery may play a role. It has been suggested that antigen leakage from surgical manipulation may have contributed to early-onset cases within 1 month postoperatively [7]; however, some reports have questioned whether cases developing several years later can be attributed to the effects of surgery [10]. It is possible that a certain period may have passed with subclinical Graves’ disease, even if TRAb and thyroid-stimulating antibody (TSAb) were produced under the influence of surgery. Indeed, most patients with Graves’ disease are reported to have subclinical disease prior to the onset of hyperthyroidism, with progression to overt hyperthyroidism occurring in up to 7% of patients annually [7, 16, 17]. For instance, Case 5 had a high TSAb level of 507% before surgery and subclinical Graves’ disease [9]. In contrast, the other reported cases showed no preoperative or immediate postoperative evidence of Graves’ disease antibodies. In the present case, pre- and postoperative TRAb and TSAb levels were unknown, but it is possible that these antibodies were either predominantly elevated or newly appeared because of surgery. Second, if the effect of surgery is limited, Graves’ disease may develop from underlying Hashimoto’s disease. Indeed, the incidence of postoperative Graves’ disease was 1.7% (2/117 patients) in those with preoperative positive anti-thyroglobulin particle agglutination and/or antithyroid microsomal particle agglutination, which is more than 10 times higher than the 0.12% (1/795 patients) observed in antibody-negative patients [10]. Moreover, 50–70% of patients with Graves’ disease have been reported to possess anti-peroxidase or anti-thyroglobulin antibodies characteristic of Hashimoto’s disease, with progression from Hashimoto’s disease to Graves’ disease occurring over a median of approximately 7 years [18]. Additionally, TSAb was negative at the time of Hashimoto’s disease diagnosis in 8/11 patients (73%) who subsequently became TSAb positive and developed Graves’ disease [18]. In the present study, one of the two patients had been diagnosed with Hashimoto’s disease preoperatively and had a negative TRAb at that time. Even if TSAb is negative at the time of Hashimoto’s disease diagnosis, continuous evaluation is recommended for early detection of Graves’ disease, especially in cases of replacement therapy [18]. In the present case, when postoperative hyperthyroidism was observed, we first considered the impact of thyroid hormone over-replacement; however, the possibility of a transition from Hashimoto’s disease to Graves’ disease should also have been considered. If TRAb had been measured during postoperative follow-up, it could have led to an earlier diagnosis. The second point of contention is that the patients were considerably older than the typical age of occurrence of Graves’ disease, being 71 and 75 years old [2, 3]. Recent research suggests that aging T cells may produce autoantibodies that cause collagen diseases such as systemic lupus erythematosus and induce chronic inflammation [19]. In Graves’ disease, the number of CD 28− T cells increases as the proportion of aging T cells increases [20]. Although the pathophysiological mechanism may not differ between early- and late-onset in Graves’ disease, the influence of immunosenescence is considered to be greater in late-onset disease [21]. The association between aging and autoimmune thyroid diseases may become clearer with further study. However, if we consider that the onset of Graves’ disease was triggered by surgery, the advanced age of the two patients in this study may simply reflect that their age at the time of surgery exceeded the general consensus age for the occurrence of Graves’ disease. This study has certain limitations. First, with only two cases, it is not possible to establish a causal relationship between surgery and Graves' disease. The 3–8-year interval between surgery and disease onset further complicates the attribution of disease onset to surgery. Additionally, preoperative antibody data were unavailable, and there were no control groups or information on patients who underwent surgery but did not develop Graves' disease. These findings are therefore observational and require validation in larger studies before clinical recommendations can be made. Second, we cannot determine how many patients underwent similar procedures without developing Graves' disease, and case reports are subject to publication bias favoring unusual outcomes. Finally, alternative explanations should be considered, including natural disease progression unrelated to surgery, genetic predisposition that manifests with age, or environmental triggers that occur coincidentally after surgery. Conclusion In summary, patients may develop Graves’ disease several years after thyroidectomy, even at an advanced age. Therefore, if hyperthyroidism occurs postoperatively, Graves’ disease should be considered in the differential diagnosis, and long-term follow-up may be warranted in select patients. In such cases, the potential value of antibody measurement for predicting Graves' disease should be investigated in larger studies.